Pembrolizumab plus chemotherapy demonstrates significant overall survival (OS) benefit vs chemotherapy as first-line treatment for locally advanced or metastatic eosophageal cancer

Results from phase 3 KEYNOTE-590 trial (n=749) showed longer median OS for pembrolizumab plus chemotherapy (12.4 months; 95% CI, 10.5-14.0) vs. 9.8 months (95% CI, 8.8-10.8) for chemotherapy alone (HR=0.73 [95% CI, 0.62-0.86]; p<0.0001)

SPS commentary:

Pembrolizumab in combination with chemotherapy also significantly improved progression-free survival (PFS), reducing the risk of disease progression by 35% (HR=0.65 [95% CI, 0.55-0.76]; p<0.0001).

Biospace Inc.